GeneDx shares plunge 49% after Q1 loss and lowered guidance, prompting securities fraud investigation.

GeneDx Holdings Corp. reported a $57.5 million loss and earnings per share of -$0.28 for Q1 2026, along with a $31.3 million write-down on its fabric genomics unit. The company also cut its full-year revenue guidance by about $65 million. Following this announcement, GeneDx's stock price dropped over 49%, triggering an investigation by law firm Barrack, Rodos & Bacine into possible securities fraud. Investors who suffered losses are encouraged to contact the firm for legal options.